Wave Life Sciences, Inc. filed an 8-K on November 18, 2026, reporting the results of its 2026 Annual Meeting of Stockholders held on November 12, 2026, including stockholder approval of an 11,000,000-share increase to the company's equity incentive plan and the re-election of nine board directors.
Key Highlights
- Equity plan expanded: Stockholders approved an amendment adding 11,000,000 shares of common stock authorized for issuance under the Amended and Restated 2021 Equity Incentive Plan.
- Annual Meeting quorum: 166,197,073 shares, representing 84% of the 197,228,058 shares eligible to vote as of the October 8, 2026 record date, were present or represented by proxy.
- Nine directors re-elected: All nine existing board nominees were re-elected to serve until the 2027 Annual Meeting, with votes ranging from approximately 120.1 million to 141.9 million shares in favor.
- Auditor ratified: Stockholders approved the ratification of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, with 165,767,838 votes in favor.
- Executive pay approved: On a non-binding, advisory basis, stockholders approved named executive officer compensation with 133,800,043 votes in favor.
Wave Life Sciences Stockholders Act on Equity Plan, Board, and Auditor at 2026 Annual Meeting
According to the filing, Wave Life Sciences, Inc. (NASDAQ:WVE) held its 2026 Annual Meeting of Stockholders on November 12, 2026. Of the 197,228,058 shares of common stock issued, outstanding, and eligible to vote as of the October 8, 2026 record date, 166,197,073 shares, or 84%, were present in person or represented by proxy, constituting a quorum.
The company disclosed that stockholders voted on four proposals. Under Proposal 3, stockholders approved an amendment to the Amended and Restated 2021 Equity Incentive Plan that increases the total number of shares of common stock authorized for issuance by 11,000,000 shares. The vote on that proposal was 119,800,336 in favor, 22,936,097 against, 82,514 abstentions, and 23,378,126 broker non-votes. The filing states that a detailed summary of the material features of the amended plan appears in the company's definitive proxy statement filed with the SEC on October 14, 2026.
Under Proposal 1, all nine director nominees were re-elected to serve until the 2027 Annual Meeting. Aik Na Tan received the highest number of votes in favor at 141,885,925, while Ken Takanashi received the lowest at 120,135,906, with 22,683,041 withheld votes. Proposal 2, the ratification of KPMG LLP as independent auditor for fiscal year 2026, passed with 165,767,838 votes in favor, 338,795 against, and 90,440 abstentions. Proposal 4, the non-binding advisory vote on named executive officer compensation, passed with 133,800,043 votes in favor and 8,866,314 against, with 152,590 abstentions.
What Was Disclosed
Wave Life Sciences reported the voting results of its November 12, 2026 Annual Meeting, including approval of an 11,000,000-share increase to its equity incentive plan, re-election of nine directors, ratification of KPMG LLP as auditor, and a non-binding advisory approval of executive compensation.




Please wait processing your request...